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Adoptive cell transfer therapy (ACT) holds a highly
promising treatment for metastatic melanoma patients.
ACT involves the ex vivo expansion of autologous antitu-
mor reactive tumor infiltrating lymphocytes and their
reinfusion into lymphodepleted patients, accompanied by
IL-2 administration. ACT demonstrates objective clinical
responsiveness in 40-50% patients, including 10-21%
complete responses. However, the mechanisms underly-
ing the observed inter-individual variability in response to
this type of therapy are not well understood. We applied
whole genome-wide association study (GWAS) using
Illumina OmniQuad 1M SNP bead array and expanded
the SNP coverage to 33M by imputation against Interna-
tional HapMap and 1,000 genomes data sets. The analysis
was performed in 208 TIL or PBMC samples undergone
adoptive therapy or high does IL-2 therapy at the Surgery
Branch, NCI. Comparisons between patients experiencing
a complete responder (CR, n=30) versus those suffering
progression of disease (PD, n=108) excluding the remin-
der partial responder patients identified 140 independent
association SNPs which covers 14 functional known
genes at a threshold p-value < 1 x 10-5. Within the chro-
mosomal crossover range (1000Kb), we observed possible
association with 405 annotated genes. The strongest
signal was rs11587096, rs4506458 on chromosome 1 and
rs7894773, rs7070986 at chromosome 10. Several genes
at those loci had known immunological function. Those
include TLR5, MIA3, TAF1A, DUSP10, DISP1, HHIPL2,
MAF177B and EIF3a, FAM45A, SFXN4, GRK5, RGS10,
TIAL1, BAG3, INPPF5 AND SEC23IP on chromosome 1
and 10 respectively. Possible functional impact of the
significant SNP on chromosome 10 at transcript level
was further validated by analyzing encoded gene exons
using Fluidigm technology. In conclusion, we have identi-
fied different loci associated with clinic outcome by
GWAS study suggesting that genetic predisposition is
one of the important component determine immune
responsiveness.
Authors’ details
1Infectious Disease and Immunogenetics Section (IDIS), Department of
Transfusion Medicine, Clinical Center and trans-NIH Center for Human
Immunology (CHI), National Institutes of Health, Bethesda, MD, USA.
2Department of Biomedical Sciences for Health, University of Milan, Milan,
Italy. 3Surgery Branch, National Cancer Institute, Bethesda, MD, USA. 4Sidra
Medical and Research Center, Doha, Qatar.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P63
Cite this article as: Sommariva et al.: Genetic inference of immune
responsiveness of melanoma cancer patients to TIL therapy. Journal for
ImmunoTherapy of Cancer 2013 1(Suppl 1):P63.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
1Infectious Disease and Immunogenetics Section (IDIS), Department of
Transfusion Medicine, Clinical Center and trans-NIH Center for Human
Immunology (CHI), National Institutes of Health, Bethesda, MD, USA
Full list of author information is available at the end of the article
Sommariva et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P63
http://www.immunotherapyofcancer.org/content/1/S1/P63
© 2013 Sommariva et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
